UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2015

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.					
Form 20-F ⊠	Form 40-F □				
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):					
dicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):					

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation for Investors – March 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has dul	y caused this report to be signed on its behalf by	the undersigned, thereunto duly authorized
---	--	--

EVOGENE LTD. (Registrant)

Date: March 24, 2015 By: /s/ Sigal Fattal

Sigal Fattal Chief Financial Officer

3

EXHIBIT INDEX

EXHIBIT NO. 99.1 DESCRIPTION A Slide Presentation for Investors – March 2015.





24 March, 2015

Safe Harbor Statement



This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

The need for innovation


How to produce more with less





Our unique proposition Solving the industry's 'big data' bottleneck






Evogene's computational platform offers a unique solution to agriculture 'big data'

Our technology platform

Combining computational power and plant science





= Under development


, 5





Our market position Business model











Seed traits: yield and abiotic stress Our motivation







■ DroughtGard Potential Update - Expanded to <u>25M acres</u> • Stacking - Valuable strategy to reach efficacy targets





Seed traits: yield and abiotic stress Current product program pipeline





On track for phase advancement in 12 to 24 months

Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results, estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to particular research or collaboration projects by us or our collaboration projects by us or our collaboration.

Seed traits: yield and abiotic stress

2014 achievements and 2015 focus



- Division Highlights
 - Broad, strategic collaborations
 - 17 product programs, most advanced in Phase II
 - More than a thousand genes under validation in partners' pipelines

Highlights 2014

- ✓ New gene optimization program incorporated in Monsanto yield & stress collaboration
- ✓ Advancements in computational platforms
 - ✓ Stacking
 → PlaNet
 - ✓ Stability ☐ GeneDex
- ✓ Improved Monocot validation system



2015 focus

 More genes under field trials in the US





- Extend collaborations and seek new ones
- Computational analysis improve tools for gene advancement



 Improved Y&S validation systems - tailored per product type








Seed traits: disease, nematodes and insects

Our motivation





Dire need for innovation in insect resistance

- Resistance rising current traits
 - Compiling evidence
 - Multiple locations US & LATAM





- One solution (Bt toxins) does not fit all
 - Sucking insectsNematode

 - Diseases














Seed traits: disease, nematodes and insects

Current product program pipeline







Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

16

Seed traits: disease, nematodes and insects





- Division Highlights
 - Active since 2007, currently 8 product programs
 - Insect resistance (IR) dedicated multi year commitment of \$10 million (2014)

Highlights 2014 2015 focus IR activity initiation -Infrastructure -Table \$10 million for IR Establishment of US R&D site ✓ Launch of 2 internal programs Marrone collaboration Seek additional collaborations IR go2market Infrastructure -Official launch of supporting technologies -Crop protection facilities Expand microbial data, metagenomics Dedicated IR personnel Expand toxin discovery capabilities IR bio-assays (US site) Supporting technologies -Microbial data, Metagenomics IR Toxin mining






Seed external: agriculture chemicals

Our motivation









Seed external: agriculture chemicals Current product pipeline



Crop	Product	Partner	Discovery Phase 1	>> Phase 2	Phase 3	>> Phase 4
Row	1. Non-selective herbicide					
Broad- leaves	2. Grasses selective herbicide					
Grasses	3. Boradleaf selective herbicide					
Corn	4. Biopesticide beet armyworm	Marrone				
Cotton	5. Biopesticide Lygus hesperus	Marrone				



Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

1 21

Seed external: agriculture chemicals 2014 achievements and 2015 focus



- Division highlights
 - 5 product programs (3 herbicides, 2 biopesticides)
 - Dedicated facilities, technologies and personnel
 - Computational discovery and validation infrastructure in place

Highlights 2014

- Discovery infrastructure
 - Target discovery launch
 - Basic screening available
 - Crop protection facility



- Leveraging pharma chemical expertise -
- Two pharma innovation providers

2015 focus

- Discovery infrastructure
 - Hit discovery launch



- Advanced chemical screening system
- Next version of PointHit platform



- Seek potential collaborations
 - Herbicides go2market



- Deliverables
 - Novel herbicides targets
 - Initiation of 1st novel chemical discovery round

| 22





Seeds (castor beans) Our motivation



Immediate: industrial uses

- Main uses: biopolymers, lubricants, paints, etc.
- Global production: c.700,000 ton → rigid demand
- Strongly dominated by Indian production 90% of export
- Main importers: China, EU, U.S.
- Premium market one of most expensive vegetable oils

Market needs:

- Secure stable supply at stable price
- Open new markets and uses




Med-long term: biofuel

- Global biodiesel production c.27bn litres
- Brazil and Argentina;
- 2 of top 5 producers 25% of worldwide production
- Mandatory blending policies:
 Brazil B6; Argentina B7
- Potential to become leading exporters

Market needs:

- 2nd gen. feedstock not relaying on food crops (soy, canola)
- Improved economics for biofuels

Biodiesel estimated production (Billion liters)







Seeds (castor beans) Current product pipeline



Castor today

- Traditional / family farming
 Handpicked
 Lack equipment
 Limited agronomic practices

 - Poor seed quality

 - Low productivityWorld avg. ~1ton/ha
- Limited supply c 1.5M ha worldwide
 - Addressing industrial uses @ \$1,500 per ton oil



Our Castor

- Modern farming

 - Large scaleFully automated
 - Advanced growth protocolsHigh quality seed
- Economic yields for biodiesel
 - Significantlyimprovedyields (100's %)
 - Rain-fed
- Increased & stable supply
 Production by commercial growers
 S5M ha potential



Seeds (castor beans) 2014 achievement and 2015 focus



- Division highlights
- Activities initiated in 2007
- Established in 2012 as a wholly owned subsidiary
- Full license to all relevant Evogene technologies
- Primary product castor bean seeds

2014 highlights

- Expanded field trials in target regions -
 - Brazil two SLC commercial farms under rotation model with soy
 - Argentina 2nd year
 - Expansion of agreement with SLC joint commercial production in 2016
- Demonstration of castor value chain in Brazil from seed to oil
- Further development of harvester with CNH

2015 focus

- Pre-commercial trials of castor towards 2016 economic targets
- Expand operations in Brazil multiple farms, partners, commercial seed production infrastructure
- Further enhancement our pipeline & advanced genomics application









Ofer Haviv, President & CEO Assaf Oron, EVP Strategy and BD

24 March, 2015